Cartiva has raised $6 million from a single investor to back its musculoskeletal foot surgical products just ahead of its first PMA review. The financing could be expanded to up to $8.5 million, according to an SEC filing. The startup has previously identified New Enterprise Associates, which has a partner on its board, as its primary investor.
New Enterprise Associates has closed a pair of funds totaling $3.15 billion to invest in information technology and healthcare companies. And while med tech may not loom particularly large for NEA, the firm does have roughly a couple of dozen active medical device portfolio companies.
A wave of venture cash continues to flood into the biotech field. And New Enterprise Associates is now back at the crest of that wave. The venture group put out word this morning that it has raised $3.1 billion for two new funds, and if history is any guide, a major part of that money will be earmarked for a new blast of global biotech investments ranging from seed to clinical-stage backing.
New Enterprise Associates Partner Carol Gallagher joins FierceBiotech Radio to talk about her journey from Big Pharma to small biotech and eventually to venture capital, along the way shedding light on just what VCs do all day.
New Enterprise Associates is one of the largest venture investors in the life sciences. And it's one of the few VC firms that also fund medical device companies as part of its broad investment strategy across information technology and healthcare.
In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund--less than three years after rolling out its latest fund with $2.6 billion.
Abbott has made its move on a trio of med tech startups focused on cardiovascular catheterization. It is buying electrophysiology startup Topera for $250 million plus undisclosed milestones and has secured the right to purchase Advanced Cardiac Therapeutics, which has a novel ablation catheter. Plus, Abbott Ventures participated in a venture round for VytronUS.
After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.
New Enterprise Associates has stepped up to back San Diego-based Tracon Pharmaceuticals, joining a syndicate that is betting $27 million on the company's two cancer therapies, including a mid-stage drug now in the clinic for soft tissue sarcoma.
On the heels of a $42 million Series F closed last fall, CVRx is picking up an additional $15 million in a debt facility from Silicon Valley Bank. But that's chump change in the long run for this startup, which has raised about $265 million since its 2001 inception.